Bausch + Lomb (NYSE:BLCO) Reaches New 52-Week Low on Analyst Downgrade
Bausch + Lomb Co. (NYSE:BLCO – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday after ...
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Medical Device Stocks Fall on Tariff Hit
President Trump’s tariffs will hit pacemakers, X-ray machines and other medical devices manufactured overseas and shipped to ...
US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...
Healio19h
Miebo tied to quick, significant dry eye symptom relief over 14 days
Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...
Dance reflections: The return of a radical new festival dedicated to movement and art
It is important, stresses Scott, to foster a dialogue between past historic works and present new works. Moreover, she adds, Dance Reflections is “magnifying,” the number of dance companies, dancers ...
Bausch + Lomb price target lowered to $15 from $17 at Stifel
Stifel lowered the firm’s price target on Bausch + Lomb (BLCO) to $15 from $17 and keeps a Hold rating on the shares. Following last week’s ...